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Abstract
Background: To investigate the daily insulin doses and the ratio of basal insulin to total daily insulin in Chinese type 2
diabetic patients who received basal bolus insulin therapy.
Methodology/Principal Findings: Totally 2480 patients prescribed with pre-meal bolus insulin and bedtime basal insulin
were included. The mean daily insulin doses was 38.22614.92 IU/day, the mean daily insulin doses per weight was
0.5860.22 IU/kg, the mean bolus insulin dose was 0.4460.17 IU/kg and the mean basal insulin dose was 0.1360.08 IU/kg.
The mean basal/total daily insulin ratio (BD/TDD) was 0.2360.08. In most patients (47.94%), the BD/TDD was between 0.20
and 0.30. Diabetic duration, BMI, HbA1c, fasting and postprandial blood glucose level were positively associated with daily
insulin dose, while age was negatively associated with daily insulin dose. Diabetic duration, BMI, HbA1c, fasting blood
glucose level, and using metformin were positively associated with BD/TDD ratio, while age, postprandial C peptide,
postprandial blood glucose level and CRE level were negatively associated with BD/TDD ratio.
Conclusions/Significance: The daily insulin doses of intensive treatment in Chinese type 2 diabetic patients was 38.22 IU/
day, the mean daily insulin doses per weight was 0.58 IU/kg, mean BD/TDD ratio was 0.23.
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Introduction
Type 2 diabetes is a progressive disease. With the advance of
the disease, many patients will need insulin to maintain good
glycemic control in order to minimize the risk of diabetic
complications. For patients inadequately controlled by oral
antihyperglycemic agents, basal insulin is recommended to be
added to the oral agent [1,2]. When glycemic control can no
longer be achieved or maintained with this therapy, then
prandial insulin is gradually added, leading to a final basal/
bolus treatment (BBT) for insulin intensification [3–5].
In clinical practice, insulin treatment needs to be highly
individualized in terms of doses and regiment in order to reach
a balance between good glycemic control and the risk of
hypoglycemia. In theory, the BBT is the ideal insulin treatment
regiment for individualized insulin treatment because of its
timing of insulin injection and adjustment is more physiological.
However, what is the proper insulin dosage of BBT and what are
the associated factors in Chinese type 2 diabetic patients are still
not clear. Moreover, what is the proper basal insulin to total
daily insulin dose ratio and the associated factors in Chinese type
2 diabetic patients are yet to be determined.
To assess the proper insulin dosage and proper basal insulin to
total daily insulin dose ratio in Chinese type 2 diabetic patients, we
made this retrospective analysis in hospitalized patients receiving
intensive insulin treatment by BBT.
Methods
1. Patients
By searching inpatient database at Peking University People’s
Hospital, we have identified 2480 type 2 diabetic patients who
were hospitalized for BBT treatment due to the poor glycemic
control at the ward of Department of Endocrinology and
Metabolism of Peking University People’s Hospital from Jan.
2005 to Dec. 2010. Reasons for BBT were as followings: 1)
Advancement of insulin treatment from basal insulin plus oral
hypoglycemic agent treatment or from treatment with only oral
hypoglycemic agents before. 2) Advancement of insulin treatment
from premixed insulin when blood glucose could not be
adequately controlled. 3) Optimizing the BBT. Patients with
diabetic ketoacidosis or ketonuria and tested positive for anti-
glutamic acid decarboxylase and islet cell antibody were excluded.
Patients prescribed other oral hypoglycemia agent except
metformin were excluded.
2. Ethics Statement
This is a retrospective study, and the data were analysed
anonymously, therefore, there is no need for informed consent.
The ethics committee of Peking University People’s Hospital has
approved this retrospective study. All the patients were patients
admitted in the department of Endocrine & Metabolism of our
hospital, and during the day of their admitted, they signed the
consent form for allowing their information to be stored in the
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also approved by the ethics committee of Peking University
People’s Hospital.
3. Insulin Initiation and Titration
According to the BBT treatment protocol of our department,
each patient admitted received insulin regimen as bolus insulin
(human insulin, Humilin R, Illy Lilly) and basal insulin (neutral
protamine Hagedorn [NPH] insulin, Humilin N, Illy Lilly). The
BBT treatment protocols were shown as follows:
A. For patients with advancement of insulin treatment from
basal insulin plus oral hypoglycemic agent treatment or from
treatment with only oral hypoglycemic agents before: 1) Start
basal-bolus regimen with NPH and human regular insulin. 2)
Discontinue oral antidiabetic drugs except metformin on
admission. 3) Start total daily insulin dose as 0.4 units/kg of
body weight/day. 4) Give one-third of total daily dose as
basal insulin (NPH) and two-third as bolus insulin(human
regular insulin). 5) The bolus insulin was injected 30 minutes
before each meal and the basal insulin was injected around
10 pm. 6) Each patient was measured for fasting and two
hour post-prandial glucose (2 hPBG) after each meal every
day. 7) The bolus insulin doses were adjusted according to
2 hPPG following insulin injection by 2,4 units per day.
The basal insulin doses were adjusted according to fasting
glucose level (FBG) of previous day by 2 units per day. 8) The
goal of fasting glucose control level is 4.0,6.0 mmol/L and
of 2 hPBG control is 5.0,8.0 mmol/L. 9) If patient develops
hypoglycemia (,4.0 mmol/l) or has symptoms of hypogly-
cemia, decrease NPH or regular insulin dose by 2 units
according to fasting glucose level or 2 hPBG.
B. For patients with advancement of insulin treatment from
premixed insulin when blood glucose could not be adequately
controlled: 1) Discontinue premixed insulin and start basal-
bolus regimen with NPH and human regular insulin. 2)
Discontinue oral antidiabetic drugs except metformin on
admission. 3) Start total daily insulin dose which was
calculated according to total insulin dose of premixed insulin
before admitted. Step 4 to 9 were as the above shown.
C. For patients with optimizing the BBT: 1) Continue the total
insulin dose of basal-bolus regimen before admitted. 2) The
bolus insulin doses were adjusted according to 2 hPBG
following insulin injection by 2,4 units per day. The basal
insulin doses were adjusted according to fasting glucose level
of previous day by 2 units per day. 3) The goal of fasting
glucose control level is 4.0,6.0 mmol/L and of 2 hPBG
control is 5.0,8.0 mmol/L. 4) If patient develops hypogly-
cemia (,4.0 mmol/l) or has symptoms of hypoglycemia,
decrease NPH or regular insulin dose by 2 units according to
fasting glucose level or 2 hPBG. 5) If the patients were
overweight and could tolerate metformin, doctors would
prescribe metformin for better glycemic control.
Among these patients, 1119 patients received insulin therapy
alone while 1361 patients received insulin combination with
metformin at a standard dose 1500 mg/day. During hospitaliza-
tion, patients were prescribed standard diabetic meal comprising
60 percent of carbohydrate, 25 percent of fat and 15 percent of
protein. The mean duration of hospital stay was 1462.4 days.
4. Biochemical and Clinical Measurements
In addition to the details of insulin treatment, data retrieved
from inpatient database included anthropometric measurements at
admission, body weight of the first day and the last day of
hospitalization were measured, 4 points capillary glucose profiles
(fasting, two hours post-breakfast, two hours post-lunch and two
hours post-supper) were measured by glucose meters (ACCU-
CHEKH, Advantage, Roche Diagnostic) during hospitalization,
biochemical measurements included fasting and 2 hour post-
prandial C-peptide (ACS180,BYAER, Fribourg, Switzerland),
HbA1c (Primus ultra2, Primus Diagnostics, MO, USA ).
5. Statistical analysis
Since the patients were admitted into the ward and discharged
from hospital at different time of first day and last day of
hospitalization, the data of insulin doses, fasting and postprandial
glucose were sporadic at first day and last day of hospitalization.
Therefore, the analyses of those data were based on the insulin
doses, 4 points glucose profile of second day and the second to last
day of hospitalization. The postprandial glucose was expressed as
the mean of three postprandial glucose levels of the day. Analyses
of insulin dose were based on insulin doses of basal and prandial
insulin on the last day of hospitalization.
All values are represented as means 6 s.d. Continuous variables
were compared using a two-sample t test while frequency of
dichotomous variables was performed by x
2 analysis. A two-sided
p#0.05 was considered significant. Multiple linear regression
analysis was used to assess the associated factors of insulin doses.
All the data was analyzed by using SPSS19.
Results
1. Characteristics and Glucose Control during
Hospitalization of these Patients
Clinical characteristics of patients were shown in Table 1. The
average age was 58.87 years old; the average diabetic duration was
11.3 years. The average HbA1c was 9.41%. When these patients
were admitted, the average fasting glucose level was 8.51 mmol/L
and the average 2 hr PBG was 13.35 mmol/L. When these
patients were discharged from hospital, the average fasting glucose
level and 2 hPPG level was 7.28 mmol/L and 8.9 7 mmol/L
respectively. Details were shown in Table 1. Clinical character-
istics of patients were also shown in Table 1.
2. Insulin Doses and Associated Factors
The mean daily insulin dose was 38.22614.92 IU. The mean
insulin dose per weight was 0.5860.22 IU/kg, among which, the
mean bolus insulin dose was 0.4460.17 IU/kg and the mean
basal insulin dose was 0.1360.08 IU/kg. Of the bolus insulin
dose, the pre-breakfast one was 0.1760.07 IU/kg, the pre-lunch
one was 0.1260.06 IU/kg, and the pre-dinner one was
0.1560.06 IU/kg, representing 38.6%, 27.3% and 34.1% of
bolus insulin dose respectively. Subgroup analysis of patients with
insulin therapy alone and patients with insulin combination with
metformin therapy showed that, compared with patients treated
with insulin and metformin, patients treated with insulin alone
showed lower daily insulin doses (35.44614.27 vs.
40.51615.06 IU/day, p=0.00), lower bolus insulin dose
(27.67611.25 vs. 30.61611.18 IU/day, p=0.00), lower basal
insulin dose (7.7764.61 vs. 9.9165.68 IU/day, p=0.00). And
when it turns to insulin doses per kilogram of body weight, patients
with insulin therapy alone showed lower insulin doses per weight
(0.5760.23 vs. 0.5960.22 IU/kg, p=0.00), and lower basal
insulin doses per weight (0.1260.07 vs. 0.1460.08 IU/kg,
p=0.00). (shown in Table 1.).
Then, multiple linear regression analysis was used to find the
associated factors with insulin dose. Insulin doses per day was used
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DBP, HbA1c, fasting and postprandial C peptide, FBG and
2 hrPBG level when admission and discharged from hospital,
creatinine level and whether or not using metformin as in-
dependent variables. Results showed that diabetic duration, BMI,
HbA1c, FBG and 2 hrPBG level when admission, FBG level when
discharged from hospital were independent associated factors and
positively with daily insulin dose, while age was negatively
associated with daily insulin dose, shown in Table 2. Subgroup
analysis of patients with insulin therapy alone and patients with
insulin combination with metformin therapy showed similar
associated factors, also shown in Table 2.
And when it turns to insulin dose per kilogram of body weight,
results showed that diabetic duration, HbA1c, FBG and 2 hrPBG
level when admission, FBG level when discharged from hospital
were independent associated factors and positively with daily
insulin dose per weight, while age, BMI were negatively associated
with insulin dose per weight, shown in Table 2. Subgroup analysis
showed that the associated factors were similar.
For further analysis, the patients were divided according to the
tertiles of those above associated factors, the average level of each
associated factor in each group of patients was shown in Table 3.
From this analysis, we can learn more details. Such as, according
to the tertiles of diabetic duration, patients were divided into three
groups as diabetic duration#7 years, between 8 and 14 years,
$15years. Daily insulin doses in these three groups of patients
were 35.60613.63, 38.87614.80 and 40.30615.88 IU/day re-
spectively, and insulin dose per weight in these three groups of
patients were 0.5360.21, 0.5860.22 and 0.6260.23 IU/kg
respectively.
3. Ratio between Basal Insulin Doses and Total Daily
Insulin Doses and Associated Factors
In all patients, the ratio between basal insulin doses and total
daily insulin doses (BD/TDD ratio) was 0.2360.08 (shown in
Table 1). Subgroup analysis showed that compared with patients
using insulin combination with metformin therapy, patients with
insulin therapy alone showed significantly lower BD/TDD ratio
(0.2260.09 vs 0.2460.08, P,0.05).
Then, multiple linear regression analysis was also used to find
the associated factors with BD/TDD ratio. Results showed that
diabetic duration, BMI, HbA1c, fasting blood glucose level when
admission and when discharged from hospital, and using
metformin were the independent associated factors and positively
with BD/TDD ratio, while age, postprandial C peptide,
postprandial blood glucose level when discharged from hospital,
and creatinine level were negatively associated with BD/TDD
ratio, shown in Table 2. Subgroup analysis showed similar
results.
Table 1. Demographics and characteristics of type 2 diabetic patients receiving BBT.
Variable All patients
Patients receiving insulin
therapy alone
Patients receiving both
insulin and metformin
N 2480 1119 1361
Male/female 1337/1143 630/489 707/654*
age (years) 58.87613.15 58.59614.09 59.11612.32
Duration of DM (years) 11.3067.96 10.6168.37 11.8767.56
BMI (kg/m
2) 24.5363.59 23.3163.49 25.5363.35
Waist hippo ratio (WHR) 0.9160.09 0.9060.11 0.9260.07
SBP (mmHg) 133.31619.38 132.71620.93 133.80618.01
DBP (mmHg) 78.30610.58 77.82610.84 78.68610.36
HbA1c (%) 9.4162.15 9.4662.43 9.3761.91
Fasting C-peptide (ng/dL) 1.5660.91 1.4460.96 1.6560.85
postprandial C-peptide (ng/dL) 3.1662.10 2.9962.24 3.2861.98
FBG (mmol/L) when admission 8.5163.00 8.2163.02 8.7562.96
2 hPBG (mmol/L) when admission 13.3565.07 13.3865.56 13.3364.66
FBG (mmol/L) Discharged from hospital 7.2861.84 7.3662.05 7.2261.65
2 hPBG (mmol/L) Discharged from hospital 8.9762.48 9.1062.67 8.8662.31
CRE (umol/L) 78.68640.02 85.88654.50 73.18622.11
bolus Insulin dose per day (IU/day) 29.29611.31 27.67611.25 30.61611.18
Basal Insulin dose per day (IU/day) 8.9465.33 7.7764.61 9.9165.68
Total Insulin dose per day (IU/day) 38.22614.92 35.44614.27 40.51615.06
Bolus Insulin doses per kilogram (IU/kg) 0.4460.17 0.4460.18 0.4460.16
Basal Insulin doses per kilogram (IU/kg) 0.1360.08 0.1260.07 0.1460.08
Total Insulin doses per kilogram (IU/kg) 0.5860.22 0.5760.23 0.5960.22
Pre-breakfast Insulin doses per kilogram (IU/kg) 0.1760.07 0.1760.07 0.1760.07
Pre-lunch Insulin doses per kilogram (IU/kg) 0.1260.06 0.1260.06 0.1260.05
Pre-supper Insulin doses per kilogram (IU/kg) 0.1560.06 0.1560.07 0.1560.06
BD/TDD ratio 0.2360.08 0.2260.09 0.2460.08
doi:10.1371/journal.pone.0038962.t001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38962The BD/TDD was then analyzed by stratifying the study
subjects with each associated factor such as age, diabetic duration,
BMI, HbA1c, C peptide level, fasting glucose and 2 hr PPG level,
and usage of metformin (Table 3).
4. Distribution of BD/TDD in Patients
Figure 1 showed the distribution of BD/TDD ratio in the
studied population in both numerically and graphic manner. The
number of patients whose BD/TDD ratio between 0.11 and 0.40
occupied 92.9%, while the number of patients whose BD/TDD
ratio no more than 0.10 occupied 4.64%, and the number of
patients whose BD/TDD ratio more than 0.40 occupied 2.46%.
In the patients with insulin thearpy alone and patients with insulin
combination with metformin, the pattern of distribution of the
BD/TDD ratio was nearly the same. (Figure 1).
Discussion
In this study, we used insulin dose information from type 2
diabetic patients hospitalized for BBT to analysis daily insulin dose
and the ratio between basal insulin (NPH) and total insulin dose
(NPH +short acting insulin), with the aim of estimating daily
requirement for basal and preprandial insulin for BBT and
Table 3. The BD/TDD ratio and insulin dose per kilogram of body weight were then analyzed by stratifying the study subject with
age, DM duration, BMI, HbA1c, C peptide level, fasting and 2h glucose level on admission and discharged from hospital, and usage
of metformin.
Variables BD/TDD ratio
insulin doses per
kilogram of body weight
Total insulin dose
per day
Age* #53 years 0.2460.09 0.5760.21 38.96614.25
54–66 years 0.2360.08 0.5960.23 39.75616.14
$67 years 0.2160.08 0.5760.22 35.90614.04
DM duration #7years 0.2260.08 0.5360.21 35.60613.63
8–14years 0.2360.09 0.5860.22 38.87614.80
$15years 0.2360.09 0.6260.23 40.30615.88
BMI* ,22.2 kg/m
2 0.2160.09 0.6360.23 34.41612.33
22.2–25.8 kg/m
2 0.2260.08 0.5660.21 36.89613.66
$25.9 kg/m
2 0.2460.09 0.5660.22 43.40616.99
HbA1c #8.2% 0.2260.09 0.5260.20 34.65613.99
8.3–10.1% 0.2360.08 0.6060.24 40.66616.14
$10.2% 0.2460.08 0.6260.21 39.98613.61
fasting C-peptide ,1.18 ng/dl 0.2360.08 0.5960.21 37.42612.54
1.18–2.04 ng/dl 0.2360.08 0.5960.21 40.32615.23
$2.05 ng/dl 0.2260.08 0.5860.23 40.98616.30
Postprandial C-peptide ,1.89 ng/dl 0.2460.08 0.6260.21 38.42612.91
1.89–3.48 0.2460.08 0.6160.22 41.84615.13
$3.49 0.2260.07 0.5560.22 38.87615.84
FBG (mmol/L) when admission * ,6.95 0.2160.08 0.5360.20 35.26614.07
6.95–9.39 0.2360.08 0.5960.22 39.39614.41
$9.4 0.2560.08 0.6460.23 42.66615.15
2 hrPBG (mmol/L) when admission * ,11.1 0.2260.09 0.5460.20 35.98613.69
11.1–15 0.2360.09 0.5960.23 39.97616.10
$15.1 0.2460.08 0.6360.22 41.34614.43
FBG (mmol/L) Discharged from hospital ,6.4 0.2260.08 0.5560.21 36.12613.18
6.4–7.5 0.2260.08 0.5160.21 38.51614.32
$7.6 0.2460.09 0.6260.24 40.55616.53
2 hrPBG (mmol/L) Discharged from hospital * ,7.8 0.2460.08 0.5860.22 37.80614.03
7.8–9.2 0.2260.08 0.5760.22 38.11614.02
$9.3 0.2160.08 0.5960.23 39.43615.78
Usage of metformin* Insulin alone 0.2260.09 0.5760.23 35.44614.27
Insulin+metformin 0.2460.08 0.5960.22 40.51615.06
Creatinine (umol/L) ,66 0.2460.08 0.6160.22 40.13615.32
66–83 0.2360.08 0.5860.22 38.58614.63
$84 0.2260.07 0.5460.22 37.12614.86
*P values among the three groups were less than 0.05.
doi:10.1371/journal.pone.0038962.t003
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38962evaluating the suitable basal/bolus ratio for intensive insulin
treatment. In addition, factors associated with insulin doses and
basal/bolus ratio were also analyzed. What unique of this study is
that insulin doses collected for analysis in this study was the doses
associated with good glycemic control (with average fasting glucose
level 7.2861.84 mmol/L and 2 hr postprandial glucose level
8.9762.48 mmol/L when discharged from hospital, and without
severe hypoglycemia) during hospitalization.
From this study, we concluded that average daily insulin dose of
Chinese type 2 diabetic patients receiving BBT was 38.22 IU/day
(0.58 IU/kg/day). Average basal insulin dose was 8.94 IU/day
(0.13 IU/kg/day) and average bolus insulin dose was 29.29 IU/
day (0.44 IU/kg/day). Of the patients receiving insulin therapy
alone or receiving insulin combination with metformin, daily
insulin dose was 35.44 IU/day (0.57 IU/kg/day) and 40.51 IU/
day (0.59 IU/kg/day) respectively. The insulin dose of Chinese
type 2 diabetic patients in our study may be different from that
reported in the Caucasians. Rosenstock et al reported in a study
[6] that eligible subjects had type 2 diabetes inadequately
controlled by previous insulin therapy plus OHAs, an average
duration of diabetes of .10 years, and baseline BMI of 36.7 kg/
m2, and the daily insulin dose of BBT was 146 IU/day (1.4 IU/
kg/day), among which the basal insulin doses was 54.9 IU/day
(0.56 IU/kg/day). Hollander et al [7]reported in a 52-week study
of BBT comparing detemir combination with aspart to glargine
combination with aspart, in the detemir group, daily detemir and
aspart doses were 0.82 U/kg and 0.36 U/kg, respectively and
total daily dose was 1.18 U/kg, while in the glargine group, daily
glargine and aspart doses were 0.59 and 0.32 U/kg, respectively,
and total daily dose was 0.91 U/kg. Umpierrez et al [8] compared
BBT (glargine/glulisine) plus OHAs to sliding-scale regular insulin
(SSI) in the inpatient management of with type 2 diabetic patients,
mean daily insulin dose was about 42 U. Another comparison they
made [9] was of inpatient insulin regimens with detemir plus
aspart versus NPH plus regular in medical patients with type 2
diabetes. Mean total daily insulin dose in the detemir/aspart group
was 57645 U, mean daily dose of detemir insulin given once daily
was 30628 U, total daily dose of aspart insulin given before meals
was 27620 U. Fonceca et al [10] made a comparison between
glargine with regular insulin and NPH with regular insulin, which
showed that in the glargine group, daily glargine and regular
insulin doses were 36.4626.5 U and 37.1628.4 U, respectively,
Figure 1. The distribution of BD/TDD of type 2 diabetic patients receiving intensive insulin therapy. Patients whose BD/TDD ratio
between 0 and 0.10 occupied 4.64%, patients whose BD/TDD ratio between 0.11 and 0.20 occupied 29.03%, patients whose BD/TDD ratio between
0.21 and 0.30 occupied 47.94%, patients whose BD/TDD ratio between 0.31 and 0.40 occupied 15.93%, patients whose BD/TDD ratio between 0.41
and 0.50 occupied 1.94%, patients whose BD/TDD ratio between 0.51 and 0.60 occupied 0.36%, patients whose BD/TDD ratio more than 0.60
occupied 0.16%. Subgroup analysis showed that: of the patients receiving insulin therapy alone, Patients whose BD/TDD ratio between 0 and 0.10
occupied 6.52%, patients whose BD/TDD ratio between 0.11 and 0.20 occupied 33.42%, patients whose BD/TDD ratio between 0.21 and 0.30
occupied 46.02%, patients whose BD/TDD ratio between 0.31 and 0.40 occupied 12.15%, patients whose BD/TDD ratio between 0.41 and 0.50
occupied 1.52%, patients whose BD/TDD ratio between 0.51 and 0.60 occupied 0.09%, patients whose BD/TDD ratio more than 0.60 occupied 0.27%.
Of the patients receiving insulin combination with metformin therapy, patients whose BD/TDD ratio between 0 and 0.10 occupied 3.16%, patients
whose BD/TDD ratio between 0.11 and 0.20 occupied 25.40%, patients whose BD/TDD ratio between 0.21 and 0.30 occupied 49.49%, patients whose
BD/TDD ratio between 0.31 and 0.40 occupied 19.02%, patients whose BD/TDD ratio between 0.41 and 0.50 occupied 2.28%, patients whose BD/TDD
ratio between 0.51 and 0.60 occupied 0.56%, patients whose BD/TDD ratio more than 0.60 occupied 0.07%. The three columns represented patients
receiving insulin alone, patients receiving insulin combination with metformin and all of the patients, respectively, from left to right.
doi:10.1371/journal.pone.0038962.g001
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regular insulin doses were 30.2622.8 U and 34.0624.1U, re-
spectively, and total daily dose was 64.2 U. Raskin et al [11]
compared insulin regimens with detemir plus aspart versus
glargine plus aspart, which showed that the mean basal insulin
doses were 0.8160.456 U/kg and 0.7560.324 U/kg for the
detemir group and the glargine group, respectively. Insulin doses
(including prandial and basal insulin doses) of all the above studies
were much higher than that concluded from our study. There may
be some reasons for the differences. First, the racial differences
might explain the heterogeneity of insulin secretion and insulin
sensitivity between Chinese and Caucasians, which may resulted
in different insulin dosage. As we know that, daily doses of BBT
reported from Japanese studies were comparable to that in
Chinese. Yokoyama et al [12] compared BBT (glargine with
aspart/lispro) to BBT (NPH with aspart/lispro), mean total daily
insulin dose in the glargine group was 42618 U, the percentage of
basal insulin was 48%, while in the NPH group, mean total daily
insulin dose was 38616 U, the percentage of basal insulin was
28%. Other studies in Japanese patients showed that total daily
insulin plus OHAs ranged from 0.31 IU/kg to 0.62 IU/kg
[13,14,15]. Second, this study is a retrospective study while those
studies in the Caucasians are random control studies or cross-
sectional studies. There might be different protocols for insulin
initiation and titration, different combination drugs and different
target of glycemic control. Therefore, there might be different
insulin dose and different BD/TDD ratio. Third, the patients
included were all admitted patients, there might be different
lifestyle intervention, different severity of the disease, different
diabetic duration, compared with the patients in the Caucasians
studies. Therefore, there might be different insulin dose and
different BD/TDD ratio. However, reasons are still not clear
at all.
According to this study, we found that patients prescribed with
higher daily insulin doses showed lower age, longer diabetic
duration, higher BMI, higher HbA1c, higher blood glucose level.
And when it turns to insulin dose per kilogram of body weight,
patients prescribed with higher insulin doses per weight also
showed the above characteristics but different in lower BMI. In
patients with insulin therapy alone, lower age, longer diabetic
duration, higher BMI, higher HbA1c, higher blood glucose level
were also associated with higher daily insulin dose, and the same
factors without BMI were associated with higher insulin doses per
weight. In patients with insulin combination with metformin
therapy, lower age, longer diabetic duration, higher BMI, higher
HbA1c, higher blood glucose level were also associated with
higher daily insulin dose, and the similar factors were associated
with higher insulin doses per weight but different in lower BMI.
In the treatment of type 2 diabetes, b-cell dysfunction and
insulin resistance are both associated with higher demand for
exogenous insulin [16]. Some factors associated with insulin doses
observed in this study were consistent with previous observations,
which showed that younger patient’s age, longer diabetic duration,
higher HbA1c, higher blood glucose level were associated with
higher insulin dose because of poor b-cell function and poor
glycemic control [16,17]. There was a different result in BMI
when analyzing associated factors for daily insulin dose and insulin
dose per weight, which showed that higher BMI was associated
with higher daily insulin dose while lower BMI was associated with
higher insulin dose per weight. It could be explained as that
patients with higher BMI always have higher body weight,
therefore they need more daily insulin dose. But when it turns to
insulin dose per weight, patients with lower BMI always have poor
b-cell function, therefore, these patients may need more insulin to
control glycemic level, but their daily insulin dose might not be
high.
According to this study, the mean BD/TDD ratio of Chinese
type 2 diabetic patients receiving BBT was 0.23. Of the patients
receiving insulin therapy alone or receiving insulin combination
with metformin, the mean BD/TDD ratio was 0.22 and 0.24
respectively. The BD/TDD ratio of a large majority (92.45%) of
patients was in the range of 0.11–0.40, and the distribution pattern
was very similar between patients receiving insulin therapy alone
and patients receiving insulin combination with metformin. These
results may suggest that these type 2 diabetic patients receiving
BBT might remain substantial insulin secretion, therefore, the
BD/TDD ratio of these patients was lower than that of type 1
diabetic patients in the Caucasians whose BD/TDD ratio was
about 0.50 [18,19]. This ratio may also be different from that of
type 2 diabetic patients in the Europeans and the Americans. In
the study that Rosenstock et al reported [6], BD/TDD ratio was
about 0.4. In Hollander et al [7] reported study, BD/TDD ratio
was about 0.69 in the determir group and 0.65 in the glargine
group respectively. In Umpierrez et al [9] reported study, BD/
TDD ratio was about 0.53. In Fonceca et al [10] reported study,
BD/TDD ratio was about 0.50 in the glargine group and 0.47 in
the NPH group respectively. However, in a study reported from
Japanese type 2 diabetic patients on intensive insulin therapy [13],
the BD/TDD ratio was in accordance with that concluded from
our study. In Yokoyama et al [12] reported study, BD/TDD ratio
was 0.48. It may suggest that the Asians need less basal insulin for
good glucose control.
According to this study, the BD/TDD ratio, was positively
associated with age, diabetic duration, BMI, HbA1c, fasting blood
glucose level, and using metformin, while negatively associated
with postprandial blood glucose level, postprandial C peptide, and
CRE level. As we know that, with the increasing of DM duration,
the b-cell function decreased, which indicated that patients might
need more basal insulin for good glycemic control, therefore, the
BD/TDD ratio became higher. Patients included in this study
were all type 2 diabetes that characterized as not only insulin
secretion deficiency but also insulin resistance. The higher level of
BMI indicated the stronger of insulin resistance, and patients with
strong insulin resistance may need more basal insulin for good
glycemic control. This could also explain why using metformin
was associated with higher BD/TDD ratio, for doctors were
suggested to use metformin in treating insulin resistance in
overweight and obese patients. According to this study, the higher
HbA1c or fasting blood glucose level was, the higher BD/TDD
ratio was. It is obvious that patients with poor glycemic control
may need more basal insulin for good fasting glycemic control, and
therefore, BD/TDD ratio was higher. For compared with the
younger one, the older patients in this study showed lower BMI
and lower HbA1c, therefore, they may need lower BD/TDD ratio
for glycemic control. As the C peptide level may reflect the
endogenous secretion of b-cell, which could be inhibited by
exogenous insulin treatment. So patients receiving more basal
insulin dosage might show good glycemic control as lower level of
postprandial blood glucose, and might show the inhibited
endogenous secretion as lower level of postprandial C peptide.
According to this study, the higher the CRE level, the lower the
BD/TDD ratio. The average level of CRE was
78.68640.02 umol/l, which indicated that the renal function of
most patients included in this study were normal. However, higher
CRE level might influence the insulin metabolism and degradation
in patients and therefore might lead to higher risk of hypoglyce-
mia. So for these patients admitted for BBT, doctors prescribed
less basal insulin in case of hypoglycemia events. Some of the
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study were consistent with previous observations [16,17].
The ratios between short acting insulin and intermediate acting
protamine of the commercial available premixed preparations are
25:75, 30:70 and 50:50 in current China marketing. However,
according to our study which showed that the mean BD/TDD
ratio of Chinese type 2 diabetic patients receiving BBT was 0.23,
those ratios might not match the real need of insulin therapy in
Chinese type 2 diabetic patients. This information might also help
clinicians and pharmacologists to choose a better ratio of premixed
insulin for individual Chinese patients.
We acknowledge the following limitations in this study. First,
this study was a retrospective study, which made it difficult to draw
firm conclusions regarding the clinical outcomes, because patients
receiving insulin treatment in this study were not originally
intended to explore the insulin dose, or the BD/TDD ratio or the
associated factors. However, these patients were all admitted
patients, and their insulin doses were titrated by experienced
doctors according to the insulin treatment protocols. Therefore,
results from these admitted patients could help us for better
learning insulin regimen in Chinese type 2 diabetic patients.
Second, patients of this study were made up of hospitalized
patients, so the results could only reflect the factors associated with
insulin treatment in admitted patients but not the out-patients.
In summary, from this study, we concluded that average daily
insulin dose of Chinese type 2 diabetic patients receiving BBT
was 38.22 IU/day (0.58 IU/kg/day). Average basal insulin dose
was 8.94 IU/day (0.13 IU/kg/day) and average bolus insulin
dose was 29.29 IU/day (0.44 IU/kg/day) and the mean BD/
TDD ratio was 0.23.
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